Koninklijke Philips’ U.S.-listed ADR (PHG) traded down about 3.28% to $27.56, with the tape showing a risk-off tone into the company’s next catalyst: first-quarter 2026 earnings scheduled for May 6, 2026. With the stock already sensitive to headline risk, investors used a down-market session to trim exposure ahead of results and any potential commentary on the lingering Respironics matter set.

Philips’ investor calendar lists May 6, 2026 as the release date for first-quarter 2026 results, followed shortly by the annual general meeting on May 8, 2026. That timing can increase volatility as traders reposition, particularly when a company has a well-known, multi-year legal/regulatory backdrop that can swing sentiment even without new filings.

Philips continues to highlight that its U.S. Respironics unit and certain subsidiaries have been cooperating with a criminal and civil U.S. Department of Justice investigation that began in 2022 related to events leading up to the recall. The company also notes additional stakeholder actions tied to the matter, including investor inquiry requests in the Netherlands around late 2025 and early 2026—factors that keep the name trading with an overhang and can exacerbate declines on weak tape days.

Because PHG is an ADR tied to a euro-based company, a firmer U.S. dollar can mechanically pressure the U.S.-listed shares even if the local listing is steadier. With markets watching macro data and the dollar strengthening versus the euro in today’s session, currency translation likely added to the downside pressure for PHG holders.